Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

Not a traditional drug phase: Endoscopic sleeve gastroplasty for Obesity

EGO-Trial is the first multicenter study in France which aims to measure the how well it works of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, how well it works, and variability of ESG practices across institutions The project is expected to generate robust, multicentric clinical evidence on the safety and how well it works of ESG in patients with obesity within the French healthcare context.

Official registry: https://clinicaltrials.gov/study/NCT07449520 · IHU Strasbourg · enrollment listed as 300

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 300 people at 12 sites. Taking part typically means a procedure as part of the study plus check-ins.

Official title (unrewritten)

Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity

Interventions: Endoscopic sleeve gastroplasty

Primary outcome (registry wording): Total Body Weight Loss

Who it is for (from inclusion criteria)

  • Ages 18 Years to 75 Years
  • Patients aged 18 to 75 years
  • Patients with a Body Mass Index (body-mass index (BMI)) ≥ 30 kg/m²
  • Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy)
  • Patients not eligible for bariatric surgery or does not wish to undergo it
  • Patients who can undergo general anesthesia
  • Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study
  • Patients who are able to fully understand the study and are willing to give their consent to participate in the study

Public study contact (from the registry)

Armelle TAKEDA

0033 390 413608

armelle.takeda@ihu-strasbourg.eu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

12 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseMontreal, Quebec
Not a traditional drug phase: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE) for Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

FAQ about this NCT record

Is NCT07449520 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07449520?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07449520?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary